Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 4, 2009, Pages 873-879

  Dongre, Vaijanath G ^a   Ghugare, Pradeep D ^a   Karmuse, Pravin ^a   Singh, Dharmendra ^b   Jadhav, Atul ^b   Kumar, Ashok ^b  

^a UNIVERSITY OF MUMBAI   (India)

^b Ipca Laboratories Ltd   (India)

Author keywords

Characterization; Chloroquine; Hydroxychloroquine; Identification; Impurities

Indexed keywords

2 [4 (7 CHLOROQUINOLIN 4 YLAMINO)PENTYLAMINO]ETHANOL; [[4 [(7 CHLORO 4 QUINOLYL)AMINO] N PENTYL] N CHLOROMETHYL N ETHYLAMINO]ETHANOL; CHLOROQUINE; HYDROXYCHLOROQUINE; N 4 (7 CHLORO 4 QUINOLINYL) 1,4 PENTANEDIAMINE; N 4 CHLOROMETHYL 1,4 PENTANEDIAMINE; N 4 ETHYLAMINE 1,4 PENTANEDIAMINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DRUG IMPURITY; DRUG STRUCTURE; FRAGMENTATION REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY;

ANTIMALARIALS; CHLOROQUINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; HYDROXYCHLOROQUINE; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 62949233971     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.01.013     Document Type: Article

References (15)

1. Valducci, Roberto, Alighieri, Tiziano, Avanessian, Serozh European Patent EP1374867 (2004).
2. Gringauz A. Introduction to Medicinal Chemistry-How Drugs Act and Why (1997), Wiley-VCH, Inc., New York, NY p. 286
3. MDa K.S., Louiea M., Krausa T., MDa J.P., Sapiraa E., Lina S., PhDb V.S., and Mda L.M. Clin. Ther. 17 (1995) 622-636
4. Tett S.E., Cutler D.J., Day R.O., and Brown K.F. J. Clin. Pharmacol. 26 (1988) 303-313
5. Fitch C.D. Science 169 (1970) 289-290
6. Savarinoa A., Luciab M.B., Giordanoc F., and Caudab R. Lancet Oncol. 7 (2006) 792-793
7. Croes K., McCarthy P.T., and Flanagan R.J. J. Anal. Toxicol. 18 (1994) 255-260
8. Dwivedi A.K., Saxena D., and Singh S. J. Pharm. Biomed. Anal. 33 (2003) 851-858
9. Volina P., and Chromatogr J.B. Biomed. Sci. Appl. 666 (1995) 347-353
10. Fieger H., Iredale J., and Wainer I.W. Chirality 5 (1993) 65-70
11. Abdelrahman A.N., Karim E.I.A., and Ibrahim K.E.E. J. Pharm. Biomed. Anal. 12 (1994) 205-208
12. Wenjin F., Chen R.N., Chen J., and Quan S.U. Chin. J. Pharm. 28 (1997) 548-550
13. ICH guideline, Impurities in new drug substances Q3A (R2), 25 October 2006, Geneva, Switzerland.
14. Gainza, and Hernandez A. Int. J. Chem. Kinet. 36 (2004) 500-509
15. McChesney E.W., Conway W.D., Banks W.F., Rogers J.E., and Shekosky J.M. J. Pharmacol. Exp. Ther. 151 (1966) 482-493